New: NCI-funded clinical trial search
Mednet Logo
CommunityHematology

Hematology

Clinical discussions on blood disorders, coagulation, transfusion medicine, and hematologic malignancies.

Recent Discussions

Do you routinely evaluate patients with collagen disorders or Ehlers-Danlos for platelet defects?

1
1 Answers

Mednet MemberInvited Expert
Hematology · University of Rochester

Yes, I routinely carry out a full hemostasis evaluation, including platelet aggregation and release studies, in patients referred to me with easy bruising and hypermobility with an increased Beighton score suggesting EDS and in those already diagnosed genetically with EDS. EDS patients typically hav...

Do you routinely consider FDG PET/CT imaging for workup of fever of unknown origin?

3
1 Answers

Mednet MemberInvited Expert
Rheumatology · Cleveland Clinic

The landscape of FUO and IUO and our clinical approach to diagnosing its cause has changed significantly over the past several decades. More sensitive microbiologic screening for infectious etiologies, including syndromic molecular panels and next-generation sequencing are now clinically available a...

Do you perform genetic testing when patients have persistent hypogammaglobulinemia after rituximab therapy?

2 Answers

Mednet Member
Allergy & Immunology · University Hospitals Cleveland Medical Center

I would not routinely perform genetic testing. Multicenter studies (Labrosse et al., PMID 33862010; and Otttaviano et al., PMID 35892275) show that genetic testing returns a low yield, <5%. Several authors suggest that the risk of persistent hypogammaglobulinemia due to PID is increased if there is ...

About Mednet

A community where doctors find answers to medicine's toughest questions.

  • Verified, credentialed physicians
  • 45,000+ members across 24 specialties
  • Free CME and MOC credit

Would you offer lung SBRT in a patient with Pulmonary Langerhans Cell Histiocytosis (PLCH)?

1
1 Answers

Mednet MemberInvited Expert
Radiation Oncology · Duke University Medical Center

Langerhans cell histiocytosis (LCH) is a clonal proliferation of Langerhans cells (dendritic cells), part of the mononuclear-phagocytic system. Some patients present with unifocal disease, often in bone. A variety of treatments are acceptable for unifocal disease, including radiation therapy. Very l...

Would you consider a patient with DLBCL to have CNS involvement if no brain lesion is seen on imaging, CSF flow cytometry is negative, but PCR is positive for MYD88 and KMT2D mutations?

3
1 Answers

Mednet MemberInvited Expert
Radiation Oncology · University of Arizona

Cerebrospinal fluid (CSF) is an ultrafiltrate of plasma contained within the ventricles of the brain and the subarachnoid spaces of the cranium and spine. It is possible that cfDNA fragments containing MYD88 and KMT2D mutations may have found their way into the CSF and thereby detected by PCR techni...

How are you deciding between available third line therapies for post-transplant relapsed DLBCL?

1
1 Answers

Mednet Member
Medical Oncology · Memorial Sloan Kettering

If a patient relapses after an autologous stem cell transplant and is a candidate for CAR T-cell therapy, I would proceed with CAR T-cell therapy given longer follow up compared to bispecific antibodies, and thus a portion of the patient can achieve a durable complete response. For patients that rel...

What is your preferred first line treatment regimen for patients with untreated transplant-ineligible MM?

10
10 Answers

Mednet MemberInvited Expert
Medical Oncology · Massachusetts General Hospital

For transplant-ineligible patients, there are many excellent choices, including RVD lite and Dara Rd. My practice has shifted to Dara Rd for several reasons: The HR for Dara Rd v. Rd which is 0.56 appears to be better than the HR for RVd v. Rd in SWOG 0777, where it was 0.712 (though it should be no...

At what lab values (ferritin, TSAT%) would you offer IV iron therapy to patients with restless leg syndrome?

3
2 Answers

Mednet MemberInvited Expert
Hematology · Georgetown University School of Medicine

1. I am hopeful that practitioners will start understanding that ferritin alone is not enough to assess iron because of its acute phase reactivity. I like to order iron parameters after a 5-9 hour fast so the serum iron is not speciously elevated and get a ferritin and TSAT. If the ferritin is <30 a...

How would you select patients for epcoritamab + R² versus R² or other regimens at second-line relapsed/refractory follicular lymphoma?

3 Answers

Mednet MemberInvited Expert
Medical Oncology · Columbia University Medical Center

In second-line relapsed/refractory follicular lymphoma, I would now view epcoritamab + R² as the preferred option for many patients who are appropriate for active immunotherapy and can tolerate the added cytopenia/infection monitoring. The EPCORE FL-1 data are compelling: ORR 95% vs 79%, CR 83% vs 5...

What is your preferred iron loading strategy for patients with anemia of chronic kidney disease?

1
4 Answers

Mednet MemberInvited Expert
Nephrology · IU Health

My preferred iron loading strategy for patients with iron-deficiency and non-dialysis dependent (NND) CKD is to administer 1 gm IV iron in a single infusion and have it paid for by the patient's health insurance. That excludes sodium ferric gluconate and iron sucrose which require 4-5 infusions to a...